5 Stocks to Watch: Week of 3/2/2026

A happy weekend to you! Here's to being prepared when the market opens on Monday — we've curated a list of top-ranked stocks in our Zen Ratings system for you to check out, including:

• AbbVie (ABBV) — Pharma powerhouse rising strong after Humira patent cliff
• Diebold Nixdorf (DBD) — Up over 130% and still climbing post-restructuring
• Okeanis Eco Tankers (ECO) — 329% EPS growth and surging 179% from its lows
• Nature's Sunshine Products (NATR) — Record sales and 42% EBITDA growth turning heads
• Tactile Systems Technology (TCMD) — 234% surge fueled by chronic disease device demand

A note from our sponsors...

1- Nature's Sunshine Products (NASDAQ: NATR)

Nature's Sunshine Products is on a remarkable growth streak — and the numbers back it up. The natural health and wellness company just posted record Q3 net sales of $128 million, with adjusted EBITDA surging 42% year-over-year. North America Digital led the charge with 52% growth, while Japan and China each topped 30%, and gross margins hit a 15-quarter high of 73.3%. Something is clearly working — here's what's driving it.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $27.50 — get current quote

Max 1-year forecast: $23.00

Why we're watching:

• Analyst support: NATR’s analyst coverage is limited — the stock has already soared past the max forecast, but this could change soon as analysts re-rate. See the ratings
• DA Davidson analyst recently maintained a Strong Buy rating, noting that Q3 established the success of the company's efforts to enhance the value proposition offered to consumers at better economics for itself, providing a basis for increased conviction in the Nature's Sunshine Products story.
• The company posted impressive Q3 results with EPS of $0.36 beating estimates by 33%, while revenue of $128.3M grew 12% year-over-year, demonstrating the effectiveness of strategic investments and cost-saving initiatives.
• Management highlighted that strategic investments in North America Digital continue to pay off with a surge in new customers coupled with strong retention yielding 52% year-over-year Digital sales growth, while Asia-Pacific markets showed exceptional 30%+ growth momentum.
• It’s our Stock of the Week. In his recent article, Zen Investor Editor-in-Chief Steve Reitmeister noted “With earnings momentum this strong, and the Zen Ratings in full agreement with the investment premise, then it’s worth taking a ride on this stock.”
• Industry ranking context: NATR is currently the #1 highest-rated stock in the Food industry, which has an Industry Rating of D, making it a standout performer in its sector.
• Zen Rating highlights: Not only is NATR an A (Strong Buy) rated stock, but it has solid Component Grades: Exceptional Financials (A grade) reflect strong balance sheet health with 0.59 debt-to-equity and healthy margins, while Growth (A grade) is supported by 21% earnings growth expectations and improving operational efficiency. See all 7 Zen Component Grades here

_______________

Nvidia: +75,710%* | Tesla: +18,231%* | Shopify: +3,507%*

Stock Advisor members saw these recommendations early. Every month for 20+ years,

this service has delivered 2 high-conviction recommendations from Motley Fool’s expert

analysts—no noise, just quality.

Over 500,000 investors trust this straightforward approach to building wealth.

See This Month’s Picks

*Returns as of 01/30/2025. Past performance is no guarantee of future results.

__________

2 - Tactile Systems Technology Inc (NASDAQ: TCMD)

Tactile Systems Technology is gaining momentum in the chronic disease treatment market. With shares up 234% from their 52-week low and projected earnings growth of 23%, the maker of the Flexitouch Plus system is expanding its footprint in an underserved space. Here’s why investors are taking notice.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $28.65 — get current quote

Max 1-year forecast: $42.00

Why we're watching:

• Analyst support: Strong Wall Street endorsement with 3 Strong Buy ratings and 1 Hold rating from 4 covering analysts following better-than-expected Q4 results. See the ratings
• BTIG's Ryan Zimmerman (a top 11% rated analyst) recently maintained his Strong Buy rating with a $38 price target, detailing the strong demand for TCMD's products and competitive advantages in a growing market.
• Piper Sandler's Adam Maeder maintained his Strong Buy rating with the Street-high $42 price target, providing in-depth analysis of market factors influencing share price and emphasizing the company's strong growth projections and market position.
• Analysts raised forecasts following Q4 earnings that beat estimates, with revenue growth of 8% and improving profit margins demonstrating operational leverage as the company scales its commercialization efforts.
• Industry ranking context: TCMD is currently the 3rd highest-rated stock in the Medical Device industry, which has an Industry Rating of C.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — TCMD demonstrates balanced strength with Value, Growth, and Momentum all earning B grades, while Financials achieves an exceptional A rating.
• Component Grades: Financials scores an outstanding A rating with strong profit margins of 10.3% and excellent asset efficiency, while Value, Growth, and Momentum all earn solid B grades reflecting well-rounded fundamentals. (See all 7 Zen Component Grades here)

3- Diebold Nixdorf (NYSE: DBD)

Diebold Nixdorf is rapidly redefining its position in the global banking technology market. With shares up 133% from their 52-week low and earnings surging 91%, the company’s post-restructuring transformation is gaining real traction. As digital banking accelerates worldwide, Diebold Nixdorf is not just recovering — it’s capturing market share and building momentum. Here’s why investors are paying attention.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $80.70 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: Solid Wall Street backing with 1 Strong Buy rating and 1 Buy rating from 2 covering analysts, reflecting confidence in the company's turnaround story. See the ratings
• Following Q4 earnings that topped estimates, several analysts have raised forecasts, highlighting the company's successful navigation of its Chapter 11 emergence and renewed focus on core banking and retail technology solutions.
• For example, DA Davidson's Matt Summerville (a top 7% rated analyst) recently maintained his Strong Buy rating with a $100 price target, believing Diebold Nixdorf is positioned well to capitalize on market opportunities with projected strong earnings growth and operational efficiencies expected to drive profitability.
• Industry ranking context: DBD is currently the 1st highest-rated stock in the App industry, which has an Industry Rating of B.
• Zen Rating highlights: DBD earns a Strong Buy or A rating from our quant ratings system — an elite tier of tickers that have historically averaged +32.52%/yr  
• Component Grades: Growth achieves an outstanding A rating alongside Sentiment also at A, while Value earns a solid B grade and Financials scores A, demonstrating the company's improving financial profile post-restructuring. (See all 7 Zen Component Grades here)

A note from our sponsors...

4- Okeanis Eco Tankers (NYSE: ECO)

Okeanis Eco Tankers just hit a 52-week high — and one look at its Q4 results tells you why. The eco-friendly crude oil transporter delivered a staggering 329% year-over-year EPS growth and 49% revenue growth, fueled by elevated spot rates across its VLCC and Suezmax fleet. With strong operational leverage adding to the momentum, this company is firing on all cylinders. Here's what you need to know.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $52.00 — get current quote

Max 1-year forecast: $55.00

Why we're watching:

• Price movement: The stock has surged 179% from its 52-week low and is trading just 0.52% below its recent high, demonstrating exceptional momentum and market confidence in the company's operational model.
• Analyst support: Strong Buy consensus from 1 analyst with focused conviction on the company's operational excellence and fleet efficiency advantages. See the ratings
• For example, B. Riley Securities analyst Liam Burke (a top 12% rated analyst) recently maintained his Strong Buy rating with a $55 price target following solid Q4 and FY 2025 earnings results. The quarter's solid results were attributable to elevated very large crude carrier and Suezmax spot rates, and robust operating leverage, which more than offset higher year-over-year operating expenses per vessel, and Burke expects the company to continue outperforming its peers due to incremental operational leverage.
• Industry ranking context: ECO is currently the #1 highest-rated stock in the Shipping industry, which has an Industry Rating of A.
• Zen Rating highlights: A (Strong Buy) stocks average +32.52%/yr — ECO is in an elite category, as evidenced by its exceptional 24% return on equity (well above the 9% industry average) and impressive 46.9% profit margins.
• Component Grades: Strong Momentum (B grade) reflects the stock's powerful 179% rise from lows, while Sentiment earns a B grade and the company maintains solid Value metrics (B grade) with a reasonable 13.26x P/E ratio despite rapid growth. See all 7 Zen Component Grades here

5- AbbVie (NYSE: ABBV)

AbbVie has navigated the Humira patent cliff and come out swinging — with a jaw-dropping 96% earnings growth and a next-generation drug portfolio in immunology and oncology that has Wall Street increasingly bullish on what's ahead.

Zen Rating: B (Buy) — see full analysis

Recent Price: $224.73 — get current quote

Max 1-year forecast: $299.00

Why we're watching:

• Analyst support: ABBV commands Wall Street confidence with 9 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings from 15 covering analysts. See the ratings
• Piper Sandler researcher David Amsellem (a top 6% rated analyst) recently maintained his Strong Buy rating with a $299 price target (33% potential upside!) noting that AbbVie's strategic acquisitions will enhance its revenue base significantly and emphasizing the company is well-positioned with recent product launches.
• Guggenheim's Vamil Divan (a top 3% rated analyst) sees significant upside potential as AbbVie continues building its post-Humira growth story.
• Industry ranking context: ABBV is currently the 4th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
• Zen Rating highlights: Buy (B) stocks average +19.88%/yr — ABBV actually ranks in the top 12% of the 4600+ stocks we track. 
• Component Grades: Safety achieves an elite A rating, while Financials scores a B, reflecting the company's strong balance sheet and consistent cash generation capabilities. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.